These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37106560)

  • 1. Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10.
    Lehrer S; Rheinstein PH
    Cancer; 2023 Jul; 129(13):2103-2104. PubMed ID: 37106560
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to "Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10%".
    Lashen AG; Toss MS; Rakha EA
    Cancer; 2023 Jul; 129(13):2105. PubMed ID: 37106558
    [No Abstract]   [Full Text] [Related]  

  • 3. Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea.
    Lee JS; Oh M; ;
    Clin Breast Cancer; 2014 Dec; 14(6):426-34. PubMed ID: 25034438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Howell SJ; Wardley AM; Armstrong AC
    J Natl Cancer Inst; 2009 Dec; 101(24):1730; author reply 1730-1. PubMed ID: 19893007
    [No Abstract]   [Full Text] [Related]  

  • 5. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.
    Ibrahim E; Al-Gahmi AM; Zeenelin AA; Zekri JM; Elkhodary TR; Gaballa HE; Fawzy EE; El sayed ME; Alzahrani MS
    Med Oncol; 2009; 26(3):372-8. PubMed ID: 19034706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
    Sun WY; Choi J; Cha YJ; Koo JS
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.
    Ueno T; Saji S; Chiba T; Kamma H; Isaka H; Itoh H; Imi K; Miyamoto K; Tada M; Sasano H; Toi M; Imoto S
    Tumour Biol; 2018 Nov; 40(10):1010428318811025. PubMed ID: 30841783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative?
    Bernstein L; Lacey JV
    J Natl Cancer Inst; 2011 Mar; 103(6):451-3. PubMed ID: 21346225
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
    Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
    Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
    Sung H; Garcia-Closas M; Chang-Claude J; Blows FM; Ali HR; Figueroa J; Nevanlinna H; Fagerholm R; Heikkilä P; Blomqvist C; Giles GG; Milne RL; Southey MC; McLean C; Mannermaa A; Kosma VM; Kataja V; Sironen R; Couch FJ; Olson JE; Hallberg E; Olswold C; Cox A; Cross SS; Kraft P; Tamimi RM; Eliassen AH; Schmidt MK; Bolla MK; Wang Q; Easton D; Howat WJ; Coulson P; Pharoah PD; Sherman ME; Yang XR
    Br J Cancer; 2016 Feb; 114(3):298-304. PubMed ID: 26679376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.
    Maisonneuve P; Disalvatore D; Rotmensz N; Curigliano G; Colleoni M; Dellapasqua S; Pruneri G; Mastropasqua MG; Luini A; Bassi F; Pagani G; Viale G; Goldhirsch A
    Breast Cancer Res; 2014 Jun; 16(3):R65. PubMed ID: 24951027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone status and demographics in early onset breast cancer patients.
    Friend KE; Perry RR; Collins JN; Britt RC; Feliberti EC
    Am Surg; 2012 Jul; 78(7):819-21. PubMed ID: 22748546
    [No Abstract]   [Full Text] [Related]  

  • 13. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman.
    Setyawati Y; Rahmawati Y; Widodo I; Ghozali A; Purnomosari D
    Asian Pac J Cancer Prev; 2018 May; 19(5):1263-1268. PubMed ID: 29801411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
    Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma.
    Ronchi A; Pagliuca F; Zito Marino F; Accardo M; Cozzolino I; Franco R
    Semin Cancer Biol; 2021 Jul; 72():114-122. PubMed ID: 32165319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging: Lighting up tumours.
    Villanueva MT
    Nat Rev Clin Oncol; 2014 May; 11(5):240. PubMed ID: 24663125
    [No Abstract]   [Full Text] [Related]  

  • 17. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role of breast pathologist in diagnostic challenges of discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis?
    Altundag K
    J Neurooncol; 2018 May; 138(1):219. PubMed ID: 29383648
    [No Abstract]   [Full Text] [Related]  

  • 20. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.